Targepeutics is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight cancer and other diseases. Our lead compound, GB-13, is currently nearing Phase I clinical trials for high-grade giloma (brain cancer), and is showing promise against other solid tumors. GB-13 is a genetically engineered recombinant protein that specifically binds and destroys cancer cells with minimal normal cell damage.
The Company is now seeking additional equity investments to advance GB-13 into Phase II clinical trials and bring a second compound, a vaccine and imaging reagents to clinical trials.
Most of today’s cancer therapies kill tumor cells, but also kill normal cells. We believe we have found a targeted way to attack just tumor cells. GB-13 begins this new direction. Cancer Immunotherapy, Head & Neck, Skin Cancer, Brain Treatment, Asthma applications and more.